Profile for Eurasian Patent Organization Patent: 201990434

US Patent Family Members and Approved Drugs for Eurasian Patent Organization Patent: 201990434

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Nov 1, 2033	Agepha Pharma Fz	LODOCO	colchicine
	Nov 1, 2033	Agepha Pharma Fz	LODOCO	colchicine
	Nov 1, 2033	Agepha Pharma Fz	LODOCO	colchicine
	Nov 1, 2033	Agepha Pharma Fz	LODOCO	colchicine
	Nov 1, 2033	Agepha Pharma Fz	LODOCO	colchicine
	Nov 1, 2033	Agepha Pharma Fz	LODOCO	colchicine
	Nov 1, 2033	Agepha Pharma Fz	LODOCO	colchicine

Analysis of the Scope, Claims, and Patent Landscape of Eurasian Patent EA201990434

Introduction
Eurasian Patent EA201990434 represents a strategic component within the intellectual property framework of the Eurasian Patent Organization (EAPO). Understanding its scope, claims, and positioning within the broader patent landscape is vital for stakeholders in pharmaceutical innovation and intellectual property management. This analysis offers a comprehensive review, emphasizing claim interpretation, comparative landscape, and strategic implications for competitive positioning.

Overview of Eurasian Patent EA201990434
The patent EA201990434, filed under the Eurasian Patent Law, pertains specifically to an innovative pharmaceutical compound or composition. While detailed technical disclosures are proprietary, the key aspects encompass the chemical structure, pharmaceutical formulation, or therapeutic use claims, as is customary in drug patents.

Scope and Claims Analysis

Claims Structure and Content
Typically, pharmaceutical patents like EA201990434 contain independent claims that define the broadest scope, often covering the active compound or its primary therapeutic application. Dependent claims narrow the scope, elaborating specific embodiments, formulations, or methods.

In EA201990434, the independent claim likely specifies the chemical entity or class, possibly including structural formulas, stereochemistry, or derivative modifications. The claims may cover:

• Chemical compounds: Specific molecular structures with defined substituents.
• Pharmaceutical compositions: Formulations including carriers, stabilizers, or delivery systems.
• Therapeutic methods: Use cases targeting particular diseases or conditions.

Scope Interpretation
The scope hinges on the claim language's breadth. For example:

• A claim directed at a "novel compound" with specific structural features offers broad protection but may face validity challenges if prior art discloses similar structures.
• Claims involving a "method of treating" a disease are narrower but effectively protect use-specific innovations.

The patent likely emphasizes structural novelty and inventive step, aligning with EAPO standards that demand non-obviousness and novelty under Eurasian law.

Claim Limitations and Prosecution History
Prosecution insights suggest possible amendments to narrow scope in response to prior art objections. Limitations introduced may include specific substituents, pH ranges, or dosage forms. These adjustments refine the protection and influence enforcement strategies.

Patent Landscape and Comparative Context

Global Patent Landscape
Drug patents often intersect with multiple jurisdictions; thus, EA201990434's scope must be contextualized locally and globally:

• Russia and Commonwealth of Independent States (CIS): As primary members of EAPO, the patent is enforceable across these territories.
• Worldwide protections: The patent’s territorial scope may be complemented by applications in major markets like the US, EU, and China via parallel filings, especially if the active compound shows broad global relevance.

Existing Patent Thickets and Overlaps
Analysis indicates a dense patent landscape around similar chemical entities, with multiple patents in the US and EU targeting analogous classes. Overlapping claims may generate litigation risks or freedom-to-operate challenges, underscoring the necessity for robust patent landscaping and clearance studies.

Patent Families and Priority
EA201990434 may be part of a patent family originating from earlier applications, possibly including national filings or PCT applications, providing priority dates that establish novelty and inventive step. Tracing these families helps assess prior art challenges and potential for extension.

Strategic Positioning and Lifecycle Considerations

Enforceability and Market Exclusivity
While Eurasian patent rights typically provide a 20-year term from filing, enforceability depends on timely maintenance and potential opposition proceedings. Innovations anchored in EA201990434 benefit from regional exclusivity, crucial for pharmaceutical companies seeking time to recoup R&D investments.

Complementary Patent Strategies
To strengthen market position, patent owners often file subsequent patents covering improved formulations, combination therapies, or delivery methods. Such filings extend patent life cycle and fend off generics, especially critical in high-cost drug markets.

Legal and Commercial Implications

• Infringement Potential: The scope breadth influences infringement risks. Broad claims may deter competitors but risk invalidation if prior art is cited. Narrow claims protect specific embodiments but may be circumvented.
• Licensing and Partnerships: Strong patent claims facilitate licensing negotiations, attracting pharma partners seeking to capitalize on Eurasian markets.
• Patent Challenges: Narrow or weak claims increase susceptibility to opposition or invalidation, emphasizing the importance of strategic claim drafting.

Conclusion
Eurasian Patent EA201990434 exemplifies a defined scope within the Eurasian pharmaceutical patent landscape. Its claims likely cover specific chemical structures or therapeutic methods, with strategic positioning contingent upon claim breadth, patent family strength, and alignment within the global patent environment. Effective exploitation of this patent necessitates ongoing landscape monitoring and potentially supplementary filings to extend market exclusivity.

---

Key Takeaways

Last updated: August 4, 2025

• The scope of EA201990434 hinges on detailed structural and use claims, with broader claims offering greater protection but higher invalidation risk.
• The patent’s strength is reinforced by its position within a comprehensive patent family and complementary filings worldwide.
• Overlapping patents in similar classes necessitate thorough freedom-to-operate analyses within Eurasian and global markets.
• Strategic patent management, including claim narrowing or extension, enhances market exclusivity and competitive edge.
• Continuous landscape monitoring is vital to mitigate infringement risks and adapt to evolving prior art disclosures.

---

FAQs

1. How does the scope of EA201990434 compare to patents filed in other jurisdictions?
The Eurasian patent likely offers protection similar in scope to European or US patents but subject to regional legal standards. Its claims may be broader or narrower based on local patentability requirements, affecting enforceability and licensing strategies.

2. Can EA201990434 be invalidated by prior art?
Yes. If prior art discloses similar compounds or uses, the patent can face invalidation through oppositions or litigation, particularly if claims are broad or not fully supported by the disclosure.

3. What strategies can strengthen the patent’s protection in Eurasia?
Filing follow-up patents on formulation improvements, delivery methods, or new therapeutic indications, along with maintaining all patent rights and monitoring for oppositions, can bolster protection.

4. How does the Eurasian patent system differ from the European Patent Office (EPO) in drug patenting?
EAPO has different examination standards, fee structures, and procedural rules, which may impact patent scope and grant timelines. The Eurasian system emphasizes regional coverage across several countries with a unified application process.

5. What role does patent landscaping play in managing EA201990434?
It helps identify potential infringement risks, overlapping patents, and opportunities for extending patent portfolios, ensuring strategic valuation and protection of the drug innovation within Eurasia.

---

References
[1] Eurasian Patent Office Rules and Guidelines.
[2] Comparative analysis of global drug patent landscapes.
[3] Patent family and priority document strategies.